Lista de obras - Erika Cecchin - Dominio Público Uruguay

A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy

artículo científico publicado en 2018

A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study

artículo científico publicado en 2018

A Pharmacogenetic Survey of Androgen Receptor (CAG)N and (GGN)N Polymorphisms in Patients Experiencing Long Term Side Effects after Finasteride Discontinuation

article

A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients

artículo científico publicado en 2015

ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.

artículo científico publicado en 2015

Androgen Receptor (AR) Gene (CAG)n and (GGN)n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia.

artículo científico publicado en 2016

Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients.

artículo científico publicado en 2018

Association of theHLA-G3′UTR polymorphisms with colorectal cancer in Italy: a first insight

artículo científico publicado en 2015

Azathioprine Biotransformation in Young Patients with Inflammatory Bowel Disease: Contribution of Glutathione-S Transferase M1 and A1 Variants.

artículo científico publicado en 2019

BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress

artículo científico publicado en 2016

BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress

artículo científico publicado en 2016

CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions

artículo científico publicado en 2020

CORRIGENDUM: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium

artículo científico publicado en 2017

Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients.

artículo científico publicado en 2005

Circulating-Free DNA Analysis in Hepatocellular Carcinoma: A Promising Strategy to Improve Patients' Management and Therapy Outcomes ⬇️

artículo científico publicado en 2019

Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy

artículo científico publicado en 2022

Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines

artículo científico publicado en 2015

Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC)

artículo científico publicado en 2019

Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype.

artículo científico publicado en 2017

Decision criteria for rational selection of homogeneous genotyping platforms for pharmacogenomics testing in clinical diagnostics.

artículo científico publicado en 2010

Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.

artículo científico publicado en 2016

Educating the Next Generation of Pharmacogenomics Experts: Global Educational Needs and Concepts

scientific article published on 25 June 2019

Estimating the Effectiveness of DPYD Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity

scientific article published on 30 May 2019

FARMAPRICE: A Pharmacogenetic Clinical Decision Support System for Precise and Cost-Effective Therapy.

artículo científico publicado en 2019

Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study

scientific article published on 05 September 2019

Genetic Variants of the TERT Gene, Telomere Length, and Circulating TERT as Prognostic Markers in Rectal Cancer Patients

artículo científico publicado en 2020

Genetic biomarkers for hepatocellular cancer risk in a caucasian population.

artículo científico publicado en 2017

Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy.

artículo científico publicado en 2014

Genetic markers of the host to predict the efficacy of colorectal cancer targeted therapy

scientific article published on 12 July 2019

Germline variability and tumor expression level of ribosomal protein gene RPL28 are associated with survival of metastatic colorectal cancer patients

artículo científico publicado en 2019

HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment.

artículo científico publicado en 2015

HLA-G 3'UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer.

artículo científico publicado en 2017

Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation

artículo científico publicado en 2018

Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS).

artículo científico publicado en 2018

Impact of DNA repair gene polymorphisms on the risk of biochemical recurrence after radiotherapy and overall survival in prostate cancer

artículo científico publicado en 2017

Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.

artículo científico publicado en 2016

Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27L.

artículo científico publicado en 2017

Improving decision making on DPYD and UGT1A1*28 patients' profiling with an innovative reimbursement strategy.

artículo científico publicado en 2018

Lack of association of CYP1 B1*3 polymorphism and ovarian cancer in a Caucasian population.

artículo científico publicado en 2004

MTHFR polymorphisms in gastric cancer and in first-degree relatives of patients with gastric cancer.

artículo científico publicado en 2009

MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin

artículo científico publicado en 2014

New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach

scientific article published on 14 June 2019

Nuclear receptors and drug metabolism for the personalization of cancer therapy

artículo científico publicado en 2016

Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer

artículo científico publicado en 2020

Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients.

artículo científico publicado en 2016

Pharmacogenetics and stomach cancer: an update.

artículo científico publicado en 2007

Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment.

artículo científico publicado en 2013

Pharmacogenetics of irinotecan.

artículo científico publicado en 2003

Pharmacogenetics of stomach cancer.

artículo científico publicado en 2003

Pharmacogenetics of the nuclear hormone receptors: the missing link between environment and drug effects?

artículo científico publicado en 2013

Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma

artículo científico publicado en 2019

Pharmacogenomics and Personalized Medicine

artículo científico publicado en 2020

Pharmacogenomics and stomach cancer.

artículo científico publicado en 2004

Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment

artículo científico

Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.

artículo científico

Pharmacology of epidermal growth factor inhibitors.

artículo científico publicado en 2007

Predictive response biomarkers in rectal cancer neoadjuvant treatment.

artículo científico

Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients

artículo científico publicado en 2016

Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.

artículo científico publicado en 2009

Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine.

artículo científico publicado en 2016

Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.

scientific article published on 05 February 2013

SNCA 3'UTR genetic variants in patients with Parkinson's disease and REM sleep behavior disorder

artículo científico publicado en 2017

Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers

article

The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer

artículo científico publicado en 2006

The genotype for DPYD risk variants in colorectal cancer patients and the related toxicity management costs in clinical practice

article

Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy

artículo científico publicado en 2010

UGT1A polymorphisms as genetic biomarkers for hepatocellular carcinoma risk in Caucasian population

artículo científico publicado en 2017

UGT1A1*28 polymorphism in ovarian cancer patients.

artículo científico publicado en 2004

Ubiquitous Pharmacogenomics (U-PGx): The time for implementation is now. An Horizon2020 program to drive pharmacogenomics into clinical practice

artículo científico publicado en 2017

Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy.

artículo científico publicado en 2004

rs4143815-PDL1, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy.

artículo científico publicado en 2019

Lista de obras de Erika Cecchin

A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy

A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study

A Pharmacogenetic Survey of Androgen Receptor (CAG)N and (GGN)N Polymorphisms in Patients Experiencing Long Term Side Effects after Finasteride Discontinuation

A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients

ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.

Androgen Receptor (AR) Gene (CAG)n and (GGN)n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia.

Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients.

Association of theHLA-G3′UTR polymorphisms with colorectal cancer in Italy: a first insight

Azathioprine Biotransformation in Young Patients with Inflammatory Bowel Disease: Contribution of Glutathione-S Transferase M1 and A1 Variants.

BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress

BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress

CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions

CORRIGENDUM: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium

Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients.

Circulating-Free DNA Analysis in Hepatocellular Carcinoma: A Promising Strategy to Improve Patients' Management and Therapy Outcomes ⬇️

Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy

Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines

Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC)

Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype.

Decision criteria for rational selection of homogeneous genotyping platforms for pharmacogenomics testing in clinical diagnostics.

Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.

Educating the Next Generation of Pharmacogenomics Experts: Global Educational Needs and Concepts

Estimating the Effectiveness of DPYD Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity

FARMAPRICE: A Pharmacogenetic Clinical Decision Support System for Precise and Cost-Effective Therapy.

Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study

Genetic Variants of the TERT Gene, Telomere Length, and Circulating TERT as Prognostic Markers in Rectal Cancer Patients

Genetic biomarkers for hepatocellular cancer risk in a caucasian population.

Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy.

Genetic markers of the host to predict the efficacy of colorectal cancer targeted therapy

Germline variability and tumor expression level of ribosomal protein gene RPL28 are associated with survival of metastatic colorectal cancer patients

HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment.

HLA-G 3'UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer.

Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation

Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS).

Impact of DNA repair gene polymorphisms on the risk of biochemical recurrence after radiotherapy and overall survival in prostate cancer

Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.

Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27L.

Improving decision making on DPYD and UGT1A1*28 patients' profiling with an innovative reimbursement strategy.

Lack of association of CYP1 B1*3 polymorphism and ovarian cancer in a Caucasian population.

MTHFR polymorphisms in gastric cancer and in first-degree relatives of patients with gastric cancer.

MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin

New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach

Nuclear receptors and drug metabolism for the personalization of cancer therapy

Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer

Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients.

Pharmacogenetics and stomach cancer: an update.

Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment.

Pharmacogenetics of irinotecan.

Pharmacogenetics of stomach cancer.

Pharmacogenetics of the nuclear hormone receptors: the missing link between environment and drug effects?

Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma

Pharmacogenomics and Personalized Medicine

Pharmacogenomics and stomach cancer.

Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment

Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.

Pharmacology of epidermal growth factor inhibitors.

Predictive response biomarkers in rectal cancer neoadjuvant treatment.

Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients

Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.

Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine.

Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.

SNCA 3'UTR genetic variants in patients with Parkinson's disease and REM sleep behavior disorder

Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers

The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer

The genotype for DPYD risk variants in colorectal cancer patients and the related toxicity management costs in clinical practice

Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy

UGT1A polymorphisms as genetic biomarkers for hepatocellular carcinoma risk in Caucasian population

UGT1A1*28 polymorphism in ovarian cancer patients.

Ubiquitous Pharmacogenomics (U-PGx): The time for implementation is now. An Horizon2020 program to drive pharmacogenomics into clinical practice

Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy.

rs4143815-PDL1, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy.